BACKGROUND: HIV-infected women have a high prevalence of human papillomavirus (HPV) infection and are more likely to be infected with HPV genotypes that are considered high-risk and have the potential for progressing to cervical cancer. The currently available HPV vaccines protect against specific HPV genotypes that may not be the most important causes of dysplasia and potentially of cervical cancer in HIV-1-infected women. African women have been underrepresented in the studies of global prevalence of HPV genotypes. METHODS: We compared the HPV genotype distribution in HIV-1-infected women from Seattle, Washington, USA and Nairobi, Kenya. The reverse line blot assay and DNA sequencing on cervicovaginal lavage (CVL) specimens were carried out. RESULTS: The most commonly detected HPV types among the women from Seattle were HPV 56, 66, MM8, and 81; in contrast HPV 53, 33, and 58 were the most common HPV genotypes detected in the CVL specimens from the women in the Nairobi cohort. The HPV types associated with low-grade squamous intraepithelial lesions (LSIL) were HPV 53 and HPV 56. HPV types 58, 52, and 16 were associated with high-grade squamous intraepithelial lesions (HSIL). CONCLUSIONS: A better understanding of HPV genotype distribution in the most affected regions of the world is essential to planning effective vaccine strategies if we are unable to demonstrate cross-protection between HPV genotypes included in the present vaccines and those prevalent in the different populations.
BACKGROUND:HIV-infectedwomen have a high prevalence of humanpapillomavirus (HPV) infection and are more likely to be infected with HPV genotypes that are considered high-risk and have the potential for progressing to cervical cancer. The currently available HPV vaccines protect against specific HPV genotypes that may not be the most important causes of dysplasia and potentially of cervical cancer in HIV-1-infectedwomen. African women have been underrepresented in the studies of global prevalence of HPV genotypes. METHODS: We compared the HPV genotype distribution in HIV-1-infectedwomen from Seattle, Washington, USA and Nairobi, Kenya. The reverse line blot assay and DNA sequencing on cervicovaginal lavage (CVL) specimens were carried out. RESULTS: The most commonly detected HPV types among the women from Seattle were HPV 56, 66, MM8, and 81; in contrast HPV 53, 33, and 58 were the most common HPV genotypes detected in the CVL specimens from the women in the Nairobi cohort. The HPV types associated with low-grade squamous intraepithelial lesions (LSIL) were HPV 53 and HPV 56. HPV types 58, 52, and 16 were associated with high-grade squamous intraepithelial lesions (HSIL). CONCLUSIONS: A better understanding of HPV genotype distribution in the most affected regions of the world is essential to planning effective vaccine strategies if we are unable to demonstrate cross-protection between HPV genotypes included in the present vaccines and those prevalent in the different populations.
Authors: G La Ruche; B You; I Mensah-Ado; C Bergeron; C Montcho; R Ramon; K Touré-Coulibaly; C Welffens-Ekra; F Dabis; G Orth Journal: Int J Cancer Date: 1998-05-18 Impact factor: 7.396
Authors: Amneris E Luque; Musaret Jabeen; Susan Messing; Christopher A Lane; Lisa M Demeter; Robert C Rose; Richard C Reichman Journal: J Infect Dis Date: 2006-07-13 Impact factor: 5.226
Authors: Howard D Strickler; Joel M Palefsky; Keerti V Shah; Kathryn Anastos; Robert S Klein; Howard Minkoff; Ann Duerr; L Stewart Massad; David D Celentano; Charles Hall; Melissa Fazzari; Susan Cu-Uvin; Melanie Bacon; Paula Schuman; Alexandra M Levine; Amanda J Durante; Stephen Gange; Sandra Melnick; Robert D Burk Journal: J Natl Cancer Inst Date: 2003-07-16 Impact factor: 13.506
Authors: Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer Journal: Int J Cancer Date: 2004-08-20 Impact factor: 7.396
Authors: Marc F D Baay; Eyrun F Kjetland; Patricia D Ndhlovu; Vanessa Deschoolmeester; Takafira Mduluza; Exenevia Gomo; Henrik Friis; Nicholas Midzi; Lovemore Gwanzura; Peter R Mason; Jan B Vermorken; Svein G Gundersen Journal: J Med Virol Date: 2004-07 Impact factor: 2.327
Authors: Jennifer R Moodley; Margaret Hoffman; Henri Carrara; Bruce R Allan; Diane D Cooper; Lynn Rosenberg; Lynette E Denny; Samuel Shapiro; Anna-Lise Williamson Journal: BMC Cancer Date: 2006-05-23 Impact factor: 4.430
Authors: M-N Didelot-Rousseau; N Nagot; V Costes-Martineau; X Vallès; A Ouedraogo; I Konate; H A Weiss; P Van de Perre; P Mayaud; M Segondy Journal: Br J Cancer Date: 2006-07-11 Impact factor: 7.640
Authors: Pragna Patel; Charles E Rose; Pamela Y Collins; Bernardo Nuche-Berenguer; Vikrant V Sahasrabuddhe; Emmanuel Peprah; Susan Vorkoper; Sonak D Pastakia; Dianne Rausch; Naomi S Levitt Journal: AIDS Date: 2018-07-01 Impact factor: 4.177
Authors: Caroline Mitchell; Jennifer E Balkus; David Fredricks; Congzhou Liu; Jennifer McKernan-Mullin; Lisa M Frenkel; Christina Mwachari; Amneris Luque; Susan E Cohn; Craig R Cohen; Robert Coombs; Jane Hitti Journal: AIDS Res Hum Retroviruses Date: 2012-11-05 Impact factor: 2.205
Authors: Eun Kyoung Park; Heerim Cho; Sun Hee Lee; Seung Geun Lee; Sang Yeup Lee; Ki Hyung Kim; Chang Hun Lee; Joo Seop Chung; Ihm Soo Kwak Journal: J Korean Med Sci Date: 2013-12-26 Impact factor: 2.153
Authors: Arati Mane; Amit Nirmalkar; Arun R Risbud; Sten H Vermund; Sanjay M Mehendale; Vikrant V Sahasrabuddhe Journal: PLoS One Date: 2012-06-19 Impact factor: 3.240
Authors: Aaron Ermel; Yan Tong; Phillip Tonui; Omenge Orang'o; Kapten Muthoka; Nelson Wong; Titus Manai; Stephen Kiptoo; Patrick J Loehrer; Darron R Brown Journal: Int J STD AIDS Date: 2021-07-07 Impact factor: 1.359